International Journal of Clinical Research

Objective To observe the clinical efficacy of sivelestat sodium in the treatment of acute pulmonary contusion and the related risk factors. Methods Sixty patients with acute pulmonary contusion who met the screening criteria from May 2023 to July 2025 were selected. The clinical data of the patients were retrospectively collected. According to different treatment regimens, the patients were divided into the control group (conventional treatment regimen) and the experimental group (conventional treatment regimen + siverestat sodium), with 30 cases in each group. The general baseline data, serum inflammatory factor index levels before and after treatment, arterial blood gas index levels, self-care ability scores, length of hospital stay and mortality rate of the two groups of patients were analyzed and compared. The χ2 test and linear regression were used to analyze the risk factors related to the prognosis of patients with acute pulmonary contusion treated with siverestat sodium. Results A total of 60 patients were included in this study. Before treatment, the PCT in the experimental group was greater than that in the control group, and the difference was statistically significant (P < 0.05). After PCT treatment, the value was less than that before treatment, and the difference was statistically significant (P < 0.05). The BADL scores of both groups were higher after treatment than before treatment, and the difference was statistically significant (P < 0.05). Before treatment, the SaO₂ in the control group was greater than that in the experimental group, and the difference was statistically significant (P < 0.05). In the control group, PaO₂ was less before treatment than after treatment, and the difference was statistically significant (P < 0.05). Univariate analysis results: Traumatic shock and abnormal liver function were the related risk factors affecting the prognosis of patients in the experimental group, and the difference was statistically significant (P < 0.05). Linear regression analysis results: Abnormal liver function was an independent risk factor affecting the prognosis of patients in the experimental group, and the difference was statistically significant (P < 0.05). Conclusion Sivelestat sodium can alleviate the inflammatory response in patients with acute pulmonary contusion and improve their self-care ability. During the treatment period, more attention should be paid to the liver function indicators of patients to assist in optimizing the treatment plan.

Acute pulmonary contusion; Sivelestat sodium; Clinical efficacy; Risk assessment